Kainova Therapeutics key facts
as of Oct 2026- Developer of medical therapeutics designed for the treatment of central nervous system (CNS) diseases and cancer.
- Kainova Therapeutics is valued at approximately $92.0M as of Oct 2026 (last reported valuation).
- It has raised $113.9M; the latest was Later Stage VC ($23.3M) in Feb 2026.
- Notable investors include Investissement Quebec, Omnes Capital, Turenne Groupe, Schroders Capital, Viva BioInnovator — 14 tracked in total.
- Status: Privately Held (backing).
Kainova Therapeutics's last reported valuation, May 2022. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Kainova Therapeutics: the Monday email on marks, rounds and moves
Kainova Therapeutics funding rounds
No funding rounds for Kainova Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Kainova Therapeutics
14+Kainova Therapeutics valuation
Kainova Therapeutics's last reported valuation was $92 million in May 2022. No priced round, secondary trade or fund mark has surfaced since.
Kainova Therapeutics investors
14 investors are on record for Kainova Therapeutics, including Investissement Quebec, Omnes Capital, Turenne Groupe and Schroders Capital.
About Kainova Therapeutics
Developer of medical therapeutics designed for the treatment of central nervous system (CNS) diseases and cancer. The company's biopharmaceutical process is dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular G protein-coupled receptors, enabling healthcare providers with innovative therapeutics that aid in the treatment of cancer.
- Sector
- Healthcare
- HQ
- Montreal, Canada
- Founded
- 2001
- Employees
- 38
- Website
- kainovatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.